SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
SYN-AKE is a synthetic tripeptide that mimics waglerin-1 from the Temple Viper (Tropidolaemus wagleri), acting as a competitive antagonist at the muscular nicotinic acetylcholine receptor to reduce facial muscle contractions and expression lines.
SYN-AKE is a synthetic peptide inspired by waglerin-1, a neurotoxic peptide found in the venom of the Temple Viper (Tropidolaemus wagleri). By competitively antagonizing the muscular nicotinic acetylcholine receptor (nAChR), SYN-AKE reduces the frequency and intensity of muscle contractions in facial expression muscles.
Overview
Waglerin-1 is a 22-amino-acid peptide from Temple Viper venom that causes paralysis by blocking nicotinic acetylcholine receptors at the neuromuscular junction. While the full waglerin peptide is far too potent and large for cosmetic use, DSM identified the minimal pharmacophoric region responsible for nAChR antagonism and synthesized a small, stable tripeptide analog suitable for topical application.
SYN-AKE differs mechanistically from other neuromuscular cosmetic peptides. While Argireline and SNAP-8 inhibit presynaptic vesicle fusion (SNARE complex), and Leuphasyl reduces presynaptic excitability via opioid receptors, SYN-AKE acts postsynaptically at the muscle cell's acetylcholine receptor itself. This makes it the only cosmetic peptide that directly targets the receptor rather than the neurotransmitter release machinery.
Mechanism of Action
SYN-AKE acts as a reversible competitive antagonist at the muscular-type nicotinic acetylcholine receptor (alpha-1 subunit containing). The mechanism proceeds as follows:
- Receptor binding: SYN-AKE competes with acetylcholine for the orthosteric binding site on the nAChR at the motor endplate
- Channel blockade: By occupying the binding site, it prevents acetylcholine from triggering ion channel opening
- Reduced depolarization: Without sodium influx through the nAChR channel, endplate potential is diminished
- Attenuated contraction: The muscle fiber receives a weaker contractile signal, resulting in reduced contraction frequency and force
Unlike the irreversible enzymatic action of botulinum toxin or the semi-permanent SNARE disruption of Argireline, SYN-AKE's competitive antagonism is fully and rapidly reversible. The effect persists only while the peptide occupies the receptor, providing a self-limiting safety mechanism.
In muscle cell contraction assays, SYN-AKE reduced contraction frequency by up to 82% at optimal concentrations, demonstrating potent but reversible neuromuscular modulation.
Research
Nicotinic Receptor Binding
In vitro binding studies confirmed SYN-AKE's selectivity for the muscular-type nAChR over neuronal subtypes. This selectivity is important because muscular nAChRs (containing alpha-1 subunits) mediate skeletal muscle contraction, while neuronal nAChRs (containing alpha-3, alpha-4, or alpha-7 subunits) are involved in cognitive and autonomic functions. The peptide's selectivity profile supports its safety for topical cosmetic use.
Comparison with Argireline
Head-to-head comparisons in DSM's in vitro assay systems suggest SYN-AKE may achieve faster onset of wrinkle smoothing compared to Argireline, potentially due to the direct receptor antagonism versus the indirect SNARE disruption mechanism. However, the two peptides target different steps in the neuromuscular cascade and can be combined for additive effects.
Clinical Anti-Wrinkle Studies
A double-blind, placebo-controlled clinical study evaluated SYN-AKE at 4% of commercial solution applied twice daily for 28 days. Lintner et al. (2009) reported that profilometric analysis demonstrated significant wrinkle depth reduction in the crow's feet area, with some subjects showing improvements within the first week of application -- a faster onset than typically observed with Argireline.
DSM's clinical documentation reports mean wrinkle depth reductions of 52% after 28 days of twice-daily application, though these results should be interpreted in the context of the specific study design and measurement methodology.
Venom Peptide Biology
The parent molecule, waglerin-1, has been extensively characterized in toxinology literature. Its selectivity for the muscular nAChR alpha-1 subunit provided the structural basis for SYN-AKE design. Molles et al. (2002) elucidated the binding interactions between waglerin-1 and the nAChR, informing the minimal peptide design.
Safety Profile
SYN-AKE demonstrates a favorable safety profile in topical cosmetic use. The competitive and reversible nature of its receptor antagonism provides an inherent safety margin. Clinical studies report no irritation, sensitization, or systemic neuromuscular effects at recommended concentrations. Topical absorption is insufficient to produce systemic receptor blockade. Standard safety testing (patch test, phototoxicity, Ames test) supports safe cosmetic use. The peptide is approved for cosmetic use in the EU and other major markets. No tachyphylaxis or tolerance development has been observed with extended use, and the effect is fully reversible upon discontinuation.
Pharmacokinetic Profile
Quick Start
- Route
- Topical (serum, cream)
Research Protocols
topical
While the full waglerin peptide is far too potent and large for cosmetic use, DSM identified the minimal pharmacophoric region responsible for nAChR antagonism and synthesized a small, stable tripeptide analog suitable for topical application. The peptide's selectivity profile supports its safety fo
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | See literature | Twice daily | 28 days(Route: Topical) |
Interactions
Peptide Interactions
Head-to-head comparisons in DSM's in vitro assay systems suggest SYN-AKE may achieve faster onset of wrinkle smoothing compared to Argireline, potentially due to the direct receptor antagonism versus the indirect SNARE disruption mechanism. However, the two peptides target different steps in the ...
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (4)
- [5]
- [1]Lintner K et al Cosmetic peptides Int J Cosmet Sci (2009)
- [2]
- [3]
Svetinorm
Svetinorm is a complex peptide bioregulator preparation derived from liver tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for hepatoprotective research, liver aging, and restoration of hepatic function. Part of the Cytomed line of tissue-specific bioregulators.
TAT-Beclin-1 Conjugate Peptide
TAT-Beclin-1 is an engineered cell-penetrating autophagy-inducing peptide combining the HIV TAT transduction domain with a Beclin-1-derived sequence. It potently induces autophagy across cell types and demonstrates broad-spectrum antiviral activity against HIV, Sindbis, chikungunya, and West Nile viruses.